title: [Effects of preinduction by mifepristone on therapeutic abortions of the second and third trimesters induced by intravenous sulprostone].
abstract: The authors investigate the effects of preinduction by administering 600 mg of mifepristone (RU486) per os before medical termination of pregnancy during the third to ninth months of pregnancy by intravenous sulprostone (Nalador). The study included a population of 35 patients treated with RU486 and then Nalador versus a population of 38 patients treated with Nalador only. The characteristics of the two groups did not show any statistically significant differences (medical, surgical and obstetric difference, indication for termination). The gestational age was lower in the RU486-Nalador group (group mean age : 20.9 weeks of amenorrhea versus 23.3, p less than 0.01). The group receiving RU486 significantly demonstrated the following : reduced time for induction of labour to modifications of the cervix (7.2 h versus 10.9 h, p less than 0.05), a higher number of rapid expulsions (within 10 h in 37.1% versus 15.7%, p less than 0.05) and a reduction of side effects (45.7% versus 71.05%, p less than 0.05). The other parameters analysed (duration of termination, total dose of prostaglandin) appeared to be better with RU486, but the values were not significantly different.
authors.affiliation: Service de Gynécologie-Obstétrique B, Hôpital de la Conception, Marseille.
authors.forename: C
authors.initials: C
authors.lastname: D'Ercole
authors.forename: B
authors.initials: B
authors.lastname: Blanc
authors.forename: L
authors.initials: L
authors.lastname: Boubli
authors.forename: E
authors.initials: E
authors.lastname: Bautrant
authors.forename: F
authors.initials: F
authors.lastname: Nadal
authors.forename: B
authors.initials: B
authors.lastname: Eyraud
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000032:Abortion, Therapeutic / Q000379:methods* / Q000592:standards; D000284:Administration, Oral; D000328:Adult; D015232:Dinoprostone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D015735:Mifepristone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D011292:Premedication / Q000379:methods* / Q000592:standards
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D015735:Mifepristone; C016767:sulprostone; D015232:Dinoprostone
vernacular_title: Effets d'une préinduction par la mifépristone sur les interruptions médicales des deuxième et troisième trimestres de grossesse réalisées par sulprostone par voie intraveineuse.